{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders%2C+Lymphoproliferative&page=46",
    "query": {
      "condition": "Disorders, Lymphoproliferative",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 7746,
    "total_pages": 775,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders%2C+Lymphoproliferative&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Disorders%2C+Lymphoproliferative&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:48:38.875Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02963493",
      "title": "A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Melphalan flufenamide (Melflufen)",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncopeptides AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2016-12-28",
      "completion_date": "2021-11-16",
      "has_results": true,
      "last_update_posted_date": "2022-11-22",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 9,
      "location_summary": "Whittier, California • Gainesville, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02963493"
    },
    {
      "nct_id": "NCT00070421",
      "title": "Study of @neWorld: A Virtual Community for Children With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Psychosocial Effects of Cancer and Its Treatment",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "complementary or alternative medicine procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Leap of Faith Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "10 Years to 15 Years"
      },
      "enrollment_count": null,
      "start_date": "2003-04",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2013-05-15",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 1,
      "location_summary": "Crystal Lake, Illinois",
      "locations": [
        {
          "city": "Crystal Lake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070421"
    },
    {
      "nct_id": "NCT03132584",
      "title": "Cyclophosphamide and Alemtuzumab In Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "High-grade B-cell Lymphoma",
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 3,
      "start_date": "2017-07-30",
      "completion_date": "2018-01-30",
      "has_results": false,
      "last_update_posted_date": "2019-01-14",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03132584"
    },
    {
      "nct_id": "NCT00602147",
      "title": "Studying Common Genetic Mutations Related to Mucositis in Patients With Multiple Myeloma Receiving High-Dose Melphalan",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mucositis",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2007-07",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2013-03-14",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00602147"
    },
    {
      "nct_id": "NCT05405309",
      "title": "RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "RP-3500",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-09-23",
      "completion_date": "2025-01-10",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405309"
    },
    {
      "nct_id": "NCT01849263",
      "title": "Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Grade 3a Follicular Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Refractory Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2013-04-02",
      "completion_date": "2027-03-19",
      "has_results": true,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01849263"
    },
    {
      "nct_id": "NCT03286114",
      "title": "Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-12-21",
      "completion_date": "2021-04-28",
      "has_results": true,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286114"
    },
    {
      "nct_id": "NCT00498914",
      "title": "Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, Large-Cell, Diffuse",
        "Lymphoma, B-Cell Refractory"
      ],
      "interventions": [
        {
          "name": "YM155",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2007-06",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2015-09-04",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 12,
      "location_summary": "Beverly Hills, California • Palo Alto, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498914"
    },
    {
      "nct_id": "NCT07092852",
      "title": "PGx Medication Safety Reviews of Persons With IDD",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Intellectual Disability, Mild",
        "Intellectual Disability, Mild to Moderate",
        "Developmental Disability"
      ],
      "interventions": [
        {
          "name": "Cheek swab for PGx testing",
          "type": "OTHER"
        },
        {
          "name": "Medication safety review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GalenusRx, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2026-12-01",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 2,
      "location_summary": "Montverde, Florida • The Bronx, New York",
      "locations": [
        {
          "city": "Montverde",
          "state": "Florida"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07092852"
    },
    {
      "nct_id": "NCT00062868",
      "title": "LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Non Hodgkin Lymphoma",
        "Lymphoepithelioma",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "LMP1/2 CTLs (ALCI - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Group C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP2 CTLs (ALSCER - Group C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion - Group A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion Group B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LMP1/2 CTLs (ALCI - Expansion Group C)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 74,
      "start_date": "2003-09",
      "completion_date": "2020-04",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-21T01:48:38.875Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062868"
    }
  ]
}